Literature DB >> 15241665

The impact of depression and fluoxetine treatment on obstetrical outcome.

R Suri1, L Altshuler, V Hendrick, N Rasgon, E Lee, J Mintz.   

Abstract

INTRODUCTION: This study prospectively followed women over the course of pregnancy to assess the impact of depression and/or antidepressant treatment on obstetrical outcome.
METHOD: Sixty-four outpatient women with an Axis I diagnosis of major depressive disorder or no psychiatric history were followed in each trimester of pregnancy with administration of the CES-D. A subset of the women with depression received treatment with fluoxetine during pregnancy. Subjects with a CES-D score greater than 16 at any time point were further assessed for the presence of an active major or minor depressive episode. Primary outcome variables included infant gestational age, birth weight, Apgar score, and admission to the neonatal intensive care unit.
RESULTS: Analyzable data were available for 62 women. No significant differences were found in outcome variables between those women with exposure to medication and/or prenatal depressed mood and those women without a history of depression.
CONCLUSIONS: In contrast to other studies, our study did not demonstrate an adverse effect of fluoxetine exposure per se on obstetrical outcome. In addition, we did not find a significant impact of depression during pregnancy on obstetrical outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15241665     DOI: 10.1007/s00737-004-0057-5

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  24 in total

Review 1.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

2.  Selective serotonin reuptake inhibitor use and risk of gestational hypertension.

Authors:  Sengwee Toh; Allen A Mitchell; Carol Louik; Martha M Werler; Christina D Chambers; Sonia Hernández-Díaz
Journal:  Am J Psychiatry       Date:  2009-01-02       Impact factor: 18.112

Review 3.  Fetal effects of psychoactive drugs.

Authors:  Amy L Salisbury; Kathryn L Ponder; James F Padbury; Barry M Lester
Journal:  Clin Perinatol       Date:  2009-09       Impact factor: 3.430

Review 4.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

Review 5.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

6.  Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapy.

Authors:  Holly J Engelstad; Robert D Roghair; Chadi A Calarge; Tarah T Colaizy; Scott Stuart; Sarah E Haskell
Journal:  Neonatology       Date:  2013-12-18       Impact factor: 4.035

Review 7.  Prenatal depression and adverse birth outcomes: an updated systematic review.

Authors:  Eynav Elgavish Accortt; Alyssa C D Cheadle; Christine Dunkel Schetter
Journal:  Matern Child Health J       Date:  2015-06

Review 8.  Interface of Women's Mental and Reproductive Health.

Authors:  Sermsak Lolak; Navid Rashid; Thomas N Wise
Journal:  Curr Psychiatry Rep       Date:  2005-06       Impact factor: 5.285

9.  Effect of prenatal selective serotonin reuptake inhibitor (SSRI) exposure on birthweight and gestational age: a sibling-controlled cohort study.

Authors:  Katerina Nezvalová-Henriksen; Olav Spigset; Ragnhild Eek Brandlistuen; Eivind Ystrom; Gideon Koren; Hedvig Nordeng
Journal:  Int J Epidemiol       Date:  2016-12-01       Impact factor: 7.196

Review 10.  Perinatal depression: treatment options and dilemmas.

Authors:  Teri Pearlstein
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.